Anesthesia for Pediatric Patients with Anti‐NMDA‐Receptor Encephalitis: a retrospective case series.

2020 ◽  
Author(s):  
Marisa Bell ◽  
Megan Friedman ◽  
Marla Matar ◽  
Shinny Sakmar ◽  
Choo Phei Wee ◽  
...  
Keyword(s):  
Nmda Receptor ◽  
Pediatric Patients ◽  
Case Series ◽  
Retrospective Case ◽  
Nmda Receptor Encephalitis ◽  
Retrospective Case Series

Early Experience with Netarsudil in Pediatric Patients: A Retrospective Case Series

2020 ◽  
Author(s):  
Patrick B. Rapuano ◽  
Alex V. Levin ◽  
Jade M. Price ◽  
Jonathan S. Myers ◽  
Daniel Lee ◽  
...  
Keyword(s):  
Pediatric Patients ◽  
Case Series ◽  
Early Experience ◽  
Retrospective Case ◽  
Retrospective Case Series

Clinical Features and Outcome of Ebola Virus Disease in Pediatric Patients: A Retrospective Case Series

2017 ◽  
Vol 182 ◽  
pp. 378-381.e1 ◽  
Author(s):  
Mads Damkjær ◽  
Frauke Rudolf ◽  
Sharmistha Mishra ◽  
Alyssa Young ◽  
Merete Storgaard
Keyword(s):  
Clinical Features ◽  
Ebola Virus ◽  
Pediatric Patients ◽  
Virus Disease ◽  
Case Series ◽  
Ebola Virus Disease ◽  
Retrospective Case ◽  
Retrospective Case Series

Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis

Neurology ◽  
2016 ◽  
Vol 88 (4) ◽  
pp. 366-370 ◽  
Author(s):  
Franziska Scheibe ◽  
Harald Prüss ◽  
Annerose M. Mengel ◽  
Siegfried Kohler ◽  
Astrid Nümann ◽  
...  
Keyword(s):  
Nmda Receptor ◽  
Therapeutic Potential ◽  
Immunosuppressive Treatment ◽  
Case Series ◽  
Retrospective Case ◽  
Delayed Treatment ◽  
Nmda Receptor Encephalitis ◽  
Bortezomib Treatment ◽  
Nmdar Encephalitis ◽  
Antibody Titers

Objective:We assessed the therapeutic potential of the plasma-cell-depleting proteasome inhibitor bortezomib in severe and therapy-refractory cases of anti–NMDA receptor (anti-NMDAR) encephalitis.Methods:Five severely affected patients with anti-NMDAR encephalitis with delayed treatment response or resistance to standard immunosuppressive and B-cell-depleting drugs (corticosteroids, IV immunoglobulins, plasma exchange, immunoadsorption, rituximab, cyclophosphamide) who required medical treatment and artificial ventilation on intensive care units were treated with 1–6 cycles of 1.3 mg/m2 bortezomib. Occurrence of adverse events was closely monitored.Results:Bortezomib treatment showed clinical improvement or disease remission, which was accompanied by a partial NMDAR antibody titer decline in 4 of 5 patients. With respect to disease severity, addition of bortezomib to the multimodal immunosuppressive treatment regimen was associated with an acceptable safety profile.Conclusions:Our study identifies bortezomib as a promising escalation therapy for severe and therapy-refractory anti-NMDAR encephalitis.Classification of evidence:This retrospective case series provides Class IV evidence that bortezomib reduces antibody titers and improves the clinical course of patients with severe anti-NMDAR encephalitis.

Management of isoniazid-monoresistant tuberculosis (Hr-TB) in Queensland, Australia: a retrospective case series

2020 ◽  
Vol 173 ◽  
pp. 106163
Author(s):  
Malcolm Wilson ◽  
Bridget O'Connor ◽  
Nicholas Matigian ◽  
Geoffrey Eather
Keyword(s):  
Case Series ◽  
Retrospective Case ◽  
Retrospective Case Series

Non-vascularized fibular autograft for resistant humeral diaphyseal nonunion: Retrospective case series

2021 ◽  
pp. 102843
Author(s):  
Ahmed Fathy Sadek ◽  
Ezzat Hassan Fouly ◽  
Ahmad Fouad Abdelbaki Allam ◽  
Alaa Zenhom Mahmoud
Keyword(s):  
Case Series ◽  
Retrospective Case ◽  
Retrospective Case Series ◽  
Fibular Autograft
Sign in / Sign up

Export Citation Format

Share Document